Centers | ||
|
|
|
UCSC Chemical Screening Center | test | Therapeutic Accelerator Program (TAP) |
We are a shared research facility dedicated to improving human health by finding therapeutic agents against a wide variety of diseases, dedicated to advancing scientific knowledge and technologies, and dedicated to education of the next generation of... |
sfgd |
Test |
Partnerships |
Events |
Jobs |
Research Collaboration and license agreementThe Drug Discovery Unit announces a partnership with Takeda, Japan’s largest pharmaceutical company, to develop possible new therapeutic treatments for tau pathology, an underlying feature in several forms of neurodegeneration, including... View all California Institute for Quantitative Biosciences (QB3) QB3 isa tri-campus organization at UC Berkeley, UC San Francisco, and UC Santa Cruz. QB3 is the University of California’s hub for innovation and entrepreneurship in the life sciences. The institute supports UC researchers and empowers... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all |
No EVENTS for listing |
No Job Posts |
